- Ketamine One (KONEF) highlights psychedelic research and announces new clinical trial
- KGK is being integrated into Ketamine One’s mental health platform, accelerating the ability to foster value creation through Ketamine’s clinic portfolio
- KGK has recently been awarded a new clinical trial contract, a research project and has also completed two studies
- In addition, Ketamine has also been busy with the Ontario-based contract manufacturer Acenzia to provide a joint solution for the production and study of psychedelic compounds
- Ketamine One Capital Limited (KONEF) is flat, trading at US$1.45 as of yesterday at close
Ketamine One Capital Limited (KONEF) is pleased to highlight several new strategic initiatives on behalf of its contract research organization, KGK Science Inc.
KGK is being integrated into Ketamine One’s mental health platform, accelerating the ability to foster value creation through Ketamine’s clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.
Being at the forefront of psychedelics research strongly positions Ketamine One and KGK to generate defendable intellectual property and secure first-mover advantages.
Further, Ketamine is pleased to report that KGK has recently been awarded a new clinical trial contract, a research project and has also completed two studies.
Some psychedelic research highlights are working with five unique clients in psychedelic drug studies including but not limited to Numinus (TSXV: NUMI) and Psyched Wellness (CSE: PSYC).
Another project Ketamine has been working towards is conducting two ongoing clinical trials, one of which is the previously announced preliminary study of Numinus’ proprietary psilocybin mushroom extract in healthy adults.
In addition, Ketamine has also been busy with the Ontario-based contract manufacturer Acenzia to provide a joint solution for the production and study of psychedelic compounds and final products.
Acenzia plans to produce psychedelic mushrooms as well as formulate and manufacture psychedelic products at their EU GMP-accredited facility.
“KGK was ahead of its time when it started in the Natural Health Products industry over 24 years ago by working with clients to provide evidence of safety and efficacy in an industry that heavily relied upon testimonials,” said Najla Guthrie, President & CEO of KGK.
“As a result of Ketamine One’s existing clinical platform and KGK’s complementary research capabilities, we are well-positioned to capitalize on the inflow of capital and talent to psychedelics-focused companies,” added Guthrie.
Founded in 1997, KGK is a North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries.
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is focused on consolidating medical clinics and becoming a North American leader in mental health treatments.
It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments.
Ketamine One Capital Limited (KONEF) is flat, trading at US$1.45 as of yesterday at close.
